The Jarvik 2015 VAD, the first and currently only continuous-flow VAD specifically designed for small children, is being assessed in the Pump for Kids, Infants, and Neonates (PumpKIN) trial. Inclusion criteria for this multicenter, prospective, single-arm feasibility study was strict. Patients who failed to meet the criteria received the Jarvik 2015 VAD under the designation of “compassionate use.” This report describes clinical experiences with two compassionate-use cases at Texas Children’s Hospital: “Compassionate” Cases of the Jarvik 2015 Ventricular Assist Device.
This report, published in ASAIO Journal, emphasizes the power consumption and hemolysis and inflammatory lab profile of the Jarvik 2015 VAD as hemocompatibility was the primary focus of the developmental and the preclinical phases.
Congratulations to the Texas Children’s co-authors for this important work:
- Joseph Spinner
- Hari Tunuguntla
- Barbara Elias
- Sebastian Tume
- Jason Mcmullen
- Rija John
- Swati Choudhry
- Jack Price
- Susan Denfield
- William Dreyer
- Iki Adachi
CITATION
Spinner JA, Tunuguntla HP, Tume SC, Elias BA, Mcmullen J, John R, Choudhry S, Price JF, Denfield SW, Dreyer WJ, Adachi I. “Compassionate” Cases of the Jarvik 2015 Ventricular Assist Device. ASAIO J. 2021 Jan 11. doi: 10.1097/MAT.0000000000001351. Epub ahead of print. PMID: 33470634.
